Provider Briefing: Amoxicillin/Clarithromycin/Lansoprazole Availability in 2026

If your patients have been reporting difficulty filling prescriptions for the Lansoprazole/Amoxicillin/Clarithromycin triple therapy (brand name Prevpac), the issue is real — even if the drug isn't on the FDA's official shortage list. This briefing covers the current availability landscape, prescribing implications, cost and access considerations, and actionable steps to ensure your H. pylori patients get treated without unnecessary delays.

Timeline: How We Got Here

The availability challenges for this triple therapy combination have developed over several years:

• 2022-2023: Amoxicillin oral formulations experienced significant shortages driven by surging demand during respiratory illness seasons. The FDA listed Amoxicillin oral presentations on its drug shortage database.
• 2023-2024: While Amoxicillin supply stabilized, fewer manufacturers continued producing the pre-packaged Prevpac combination kit. Market consolidation reduced the number of available suppliers.
• 2024-2025: Updated ACG guidelines formally recommended Bismuth Quadruple Therapy as a first-line option alongside traditional Clarithromycin triple therapy, reflecting growing evidence of Clarithromycin resistance. This further reduced demand for the Prevpac kit.
• 2026: The pre-packaged kit remains available from generic manufacturers but is not routinely stocked by most retail pharmacies. Individual components remain widely available.

Prescribing Implications

The shift away from the combination pack has several practical implications for prescribers:

Clarithromycin Resistance Considerations

National Clarithromycin resistance rates among H. pylori isolates now exceed 15-20% in many U.S. regions. The 2024 ACG guidelines recommend that Clarithromycin-based triple therapy should only be used as first-line treatment in regions where local resistance rates are confirmed to be below 15%, or after susceptibility testing.

If you're prescribing Amoxicillin/Clarithromycin/Lansoprazole, consider whether Clarithromycin resistance testing has been performed or whether local resistance data supports this choice.

FDA Heart Risk Warning for Clarithromycin

In 2018, the FDA issued a safety communication warning that Clarithromycin may be associated with increased risk of heart problems or death, potentially occurring years after a short course, in patients with established coronary heart disease. For patients with significant cardiac history, consider alternative H. pylori regimens that do not include Clarithromycin.

Prescribing Individual Components vs. Combination Kit

When prescribing triple therapy, writing three separate prescriptions for Lansoprazole 30 mg, Amoxicillin 500 mg, and Clarithromycin 500 mg rather than a single prescription for the Prevpac combination kit offers several advantages:

• Better availability: Individual generics are stocked at virtually all pharmacies
• Lower cost: $30-$50 total for individual generics vs. $241-$900 for the combination kit
• Insurance coverage: Individual components rarely require prior authorization; the combination kit sometimes does
• Faster fulfillment: No need to wait for a specialty order or transfer

Current Availability Picture

As of early 2026:

• Prevpac combination kit: Available from select generic manufacturers but not routinely stocked by most chain pharmacies. Independent pharmacies may stock it or can order it within 24-48 hours.
• Lansoprazole 30 mg capsules: Widely available at all pharmacies. OTC versions (Prevacid 24HR, 15 mg) are available but not appropriate for H. pylori treatment.
• Amoxicillin 500 mg capsules: Widely available. Post-2023 supply has normalized in most regions.
• Clarithromycin 500 mg tablets: Available but may have limited stock at pharmacies with lower prescribing volume for macrolides.

Cost and Access Landscape

Understanding the cost landscape helps when counseling patients:

• Prevpac combination kit (retail): $800-$900
• Generic combination kit with coupon: ~$241 (GoodRx)
• Individual components at retail: Lansoprazole ~$15-$30, Amoxicillin ~$4-$10, Clarithromycin ~$15-$40
• Individual components with coupons: Total $30-$50
• Insurance co-pay: Typically $10-$75 for the combination kit; individual components may have lower tier co-pays

For patients with financial hardship, the individual components can also be found at pharmacies with $4 generic programs (e.g., Walmart, Costco).

Tools and Resources for Your Practice

Medfinder for Providers allows you to check real-time pharmacy stock for any medication, including the Amoxicillin/Clarithromycin/Lansoprazole combination and its individual components. You can direct patients to Medfinder or use it within your practice to identify which pharmacies near the patient have the medication in stock before sending the prescription.

Additional resources:

• For patients struggling with cost: Direct them to our savings guide which covers coupons, discount cards, and patient assistance programs.
• For patients having trouble finding it: Our in-stock finder guide walks patients through the process step by step.
• For H. pylori treatment alternatives: See our clinical overview of alternative regimens.

Alternative Regimens at a Glance

For cases where Clarithromycin triple therapy is not the best fit — whether due to availability, resistance, cost, or patient factors — here are the current evidence-based alternatives:

• Bismuth Quadruple Therapy (BQT): PPI + Bismuth Subsalicylate + Metronidazole + Tetracycline for 14 days. ACG first-line recommendation. Eradication rate: 85-90%. Cost: $30-$80 generic.
• Vonoprazan/Amoxicillin (Voquezna Dual Pak): Vonoprazan 20 mg + Amoxicillin 1 g BID for 14 days. FDA-approved. Simpler regimen. Cost: $400-$600 brand.
• Rifabutin Triple Therapy (Talicia): Omeprazole/Amoxicillin/Rifabutin TID for 14 days. FDA-approved. Low resistance rates. Cost: $500-$800 brand.
• Levofloxacin Triple Therapy: PPI + Amoxicillin + Levofloxacin BID for 14 days. Salvage therapy. Cost: $20-$60 generic. Use cautiously given fluoroquinolone safety profile.

Looking Ahead

The trend in H. pylori treatment is moving toward susceptibility-guided therapy and away from empiric Clarithromycin-based triple therapy. As resistance patterns evolve and newer agents like Vonoprazan become more widely available, the Amoxicillin/Clarithromycin/Lansoprazole combination will likely continue to decline in use — though it remains a valid option when Clarithromycin susceptibility is confirmed.

For practices that frequently manage H. pylori, consider establishing protocols that include:

1. Local or empiric resistance-guided antibiotic selection
2. Default prescribing as individual components rather than the combination kit
3. Integration of real-time pharmacy availability tools like Medfinder
4. Patient education materials on treatment adherence and cost-saving options

Final Thoughts

The practical availability of Amoxicillin/Clarithromycin/Lansoprazole as a combination kit is limited in 2026, but the individual components remain accessible and affordable. By prescribing components separately, staying current on resistance data, and using tools like Medfinder for Providers, you can ensure your H. pylori patients start treatment without unnecessary pharmacy delays.

For a patient-facing guide on helping patients find this medication, see How to Help Your Patients Find Amoxicillin/Clarithromycin/Lansoprazole in Stock.